A groundbreaking cancer immunotherapy is showing unexpected promise in treating autoimmune diseases, with early clinical trials revealing that patients with severe lupus, scleroderma, and multiple sclerosis are experiencing significant symptom improvement or even reversal. The approach, called CAR T-cell therapy, works by genetically engineering a patient's own immune cells to attack the faulty immune response driving autoimmune disease, rather than just suppressing symptoms with long-term medications.

What Is CAR T-Cell Therapy and How Could It Treat Autoimmune Disease?

CAR T-cell therapy was originally developed to fight cancer by training a patient's T cells (a type of white blood cell) to recognize and destroy cancer cells. Researchers at institutions like Roswell Park Comprehensive Cancer Center are now exploring whether the same approach could reset the immune system in people with autoimmune diseases, where the body mistakenly attacks its own healthy tissues and organs.

Unlike current autoimmune treatments that suppress the immune system broadly, CAR T-cell therapy aims to target the specific faulty immune response. The goal is what researchers call an "immune reset," which could potentially allow patients to stop taking daily medications altogether.

"Patients with severe lupus and lupus nephritis, scleroderma, even other neurologic conditions such as MS and stiff person syndrome, patients who have undergone this treatment have experienced significant improvement in their symptoms, if not reversal," explained Dr. Alicia Lieberman, who is leading the research at Roswell Park Comprehensive Cancer Center.

Dr. Alicia Lieberman, Roswell Park Comprehensive Cancer Center

Why Do Autoimmune Diseases Need a New Treatment Approach?

An estimated 8 percent of the U.S. population lives with an autoimmune disease, though the exact number of different autoimmune conditions remains unclear, with researchers estimating between 80 to 150 distinct diseases. Many of these conditions are chronic, debilitating, and require one or more daily medications that work by dampening the immune response.

Current treatments come with significant limitations and trade-offs. Most existing medications are immunosuppressive, meaning they weaken the immune system to reduce inflammation and prevent the body from attacking itself. However, this approach leaves patients more vulnerable to infections and carries various side effects.

The challenge with traditional treatments is that they require lifelong management. Patients must take medications indefinitely to control symptoms, and there is no cure for most autoimmune diseases. This is why researchers are investigating whether CAR T-cell therapy could offer a fundamentally different solution: a one-time treatment that could potentially provide lasting relief.

How to Understand the Potential Benefits of This New Approach

• One-Time Treatment: Unlike daily pills, infusions, or injections, CAR T-cell therapy aims to be a single intervention that could provide long-lasting or permanent relief from autoimmune disease symptoms.
• Immune System Reset: Rather than suppressing the entire immune system, the therapy targets the specific faulty immune response, potentially allowing the immune system to function normally again without ongoing medication.
• Symptom Reversal: Early trial results show patients with severe lupus, lupus nephritis, scleroderma, multiple sclerosis, and stiff person syndrome experiencing significant improvement or even reversal of symptoms, not just symptom management.

What Stage Are These Clinical Trials At?

The research is still in early clinical trial phases, but the preliminary results are encouraging enough that Roswell Park Comprehensive Cancer Center is actively enrolling patients. Researchers are currently studying how long the immune reset lasts and measuring the treatment's effectiveness across different autoimmune conditions.

The trials are expanding to include patients with severe autoimmunity, and scientists are working to understand the durability of the treatment. One of the key questions researchers are investigating is whether the immune reset is permanent or whether patients might eventually need additional treatment.

This approach represents a significant shift in how researchers think about treating autoimmune diseases. Rather than accepting that patients will need lifelong immunosuppressive therapy, CAR T-cell therapy offers the possibility of actually correcting the underlying immune dysfunction. If successful, this could transform treatment for millions of people living with conditions like lupus, rheumatoid arthritis, and multiple sclerosis, potentially eliminating the need for daily medications and their associated side effects.